Compare VABK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | CCCC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.8M | 240.3M |
| IPO Year | N/A | 2020 |
| Metric | VABK | CCCC |
|---|---|---|
| Price | $40.47 | $2.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 9.1K | ★ 1.4M |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ 14.22 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $56,512,000.00 | $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.28 | ★ N/A |
| Revenue Growth | ★ 10.39 | N/A |
| 52 Week Low | $33.66 | $1.09 |
| 52 Week High | $44.57 | $5.10 |
| Indicator | VABK | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 62.08 |
| Support Level | $38.11 | $2.29 |
| Resistance Level | $39.38 | $2.63 |
| Average True Range (ATR) | 0.90 | 0.15 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 100.00 | 92.41 |
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.